Profile
Harvey N.
Masonson is former Senior Vice President-Clinical Development at IVERIC bio, Inc., former Vice President-Clinical Development at Gensight Biologics SA, former Assistant Director-Clinical Safety at Bristol Myers Squibb Co., former Director-Clinical Research at Sanofi-Synthelabo, Inc. and former Vice President-Clinical Development & Drug Safety at (OSI) Eyetech.
Dr. Masonson received a doctorate from Icahn School of Medicine at Mount Sinai.
Former positions of Harvey N. Masonson
Companies | Position | End |
---|---|---|
GENSIGHT BIOLOGICS S.A. | Chief Tech/Sci/R&D Officer | 2018-12-31 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Corporate Officer/Principal | - |
Sanofi-Synthelabo, Inc. | Chief Tech/Sci/R&D Officer | - |
IVERIC BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Harvey N. Masonson
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GENSIGHT BIOLOGICS S.A. | Health Technology |
Private companies | 3 |
---|---|
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Health Technology |
IVERIC bio, Inc.
IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Sanofi-Synthelabo, Inc. | Health Technology |